On May 10, 2024 Cytimm, a clinical-stage company focused on the development of IL-2 based therapeutics for cancer, autoimmune diseases, and neurodegenerative diseases, reported that Dr. Haining Huang, Co-Founder and Chief Executive Officer, would present a corporate overview next month at the 2024 BIO International Convention in San Diego (Press release, Cytimm Therapeutics, MAY 10, 2024, View Source [SID1234646047]). The presentation is set for 11:00 a.m. PDT on Wednesday, June 5, 2024 in Company Presentation Theater 1 in Hall A of the Exhibition Hall at the San Diego Convention Center.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Huang will provide an overview of Cytimm’s strategies and innovative technologies in decoupling the two opposite functions of IL-2 and the development of the two proprietary IL-2 based drugs, CTM103 and CTM201.
CTM103 is a mRNA drug that encodes HSA-IL2v fusion protein, for the treatment of solid tumors. This intravenously delivered drug can efficiently and continuously expresses IL2v with a significantly prolonged half-life. Clinical trials of CTM103 as monotherapy or in combination with Pembrolizumab demonstrated good safety andPK profiles as well as robust immune stimulatory activity in promoting CD8 T cells and NK cells proliferation. Encouraging signs of antitumor efficacy warrants more dose escalations and cohort expansions in selected tumor indication like NSCLC, HNSCC, RCC, melanoma and others.
CTM201 is the first Treg specific long-acting PEG-IL2 without compromising its bioactivity. Cytimm, for the first time, identified the ideal PEGylation strategy for IL-2 with improved activity, stability and functionality. Based on our proprietary PEGylation technology platform, CTM201 was developed as the immune suppressor for inflammatory diseases including autoimmune diseases and neurodegenerative diseases. FIH studies in ALS volunteers demonstrated excellent safety profile and robust Treg specific amplification.
In the presentation, we will highlight our recent progress in developing next-generation IL-2 based therapies in cancer and chronic inflammatory indications. This is an exciting time for Cytimm, and we look forward to sharing our views and progresses with the community at the BIO conference in San Diego. BIO is the industry’s largest and most prestigious event and we appreciate the selection of Cytimm as a presenting company that will be featured in the partnering section of the conference.
Cytimm will also hold One-on-One meets with potential partners in the event. To schedule a meeting at the BIO International Convention with Cytimm, please submit a meeting request through the BIO One-on-One Partnering platform. For more information, please visit BIO websites or send an e-mail to Cytimm at [email protected].